Q2 2025 Ekso Bionics Holdings Inc Earnings Call Transcript
Key Points
- Ekso Bionics Holdings Inc (EKSO) is confident in closing a significant portion of deferred multi-device Enterprise Health sales by year-end.
- The company has launched eksoUniversity, a virtual platform providing continuing education courses to physical therapists, which could generate incremental revenue.
- Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025.
- Ekso Bionics Holdings Inc (EKSO) has partnered with PRIA Healthcare to enhance market access and commercialization of the Ekso Indego Personal device.
- The company is leveraging AI capabilities through the NVIDIA Connect program to enhance its exoskeleton technology platforms.
- Ekso Bionics Holdings Inc (EKSO) experienced a significant revenue decline in Q2 2025, with revenues dropping to $2.1 million from $5 million in Q2 2024.
- Gross profit and gross margin decreased due to lower Enterprise Health device sales and increased shipping costs.
- The company reported a net loss of $2.7 million for Q2 2025, compared to a net loss of $2.4 million in Q2 2024.
- There are short-term delays in completing significant multi-device Enterprise Health sales, impacting revenue.
- A small percentage of US customers have delayed purchases due to loss of federal grants and economic uncertainties.
Greetings, and welcome to the Ekso Bionics second-quarter 2025 financial results conference call. (Operator Instructions) It is now my pleasure to introduce your host, Stephen Kilmer, Investor Relations. Thank you. You may begin.
Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics released financial results for the second quarter ended June 30, 2025. A copy of the press release is available on our website.
I would like to point out that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements.
All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, our ability
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
